Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 14, 2022 - Issue
Submit an article Journal homepage
141
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes

Shahla Bari1 Department of Hematology/Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
David Boulware2 Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Jiannong Li2 Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Loretta Loftus3 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Aixa Soyano Muller3 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Zena Jameel4 Department of Anatomic and Clinical Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Hung Khong3 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Brian J Czerniecki3 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
&
Ricardo LB Costa3 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3303-3234View further author information
ORCID Icon show all
Pages 199-210 | Published online: 04 Dec 2023

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. 2020;70(1):7–30. doi:10.3322/caac.21590
  • Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.5858/134.7.e48
  • Landmann A, Farrugia DJ, Zhu L, et al. Low Estrogen Receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? Am J Clin Pathol. 2018;150(1):34–42. doi:10.1093/ajcp/aqy028
  • Prabhu JS, Korlimarla A, Desai K, et al. A majority of low (1–10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer. 2014;5(2):156–165. doi:10.7150/jca.7668
  • Raghav KP, Hernandez-Aya LF, Lei X, et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118(6):1498–1506. doi:10.1002/cncr.26431
  • Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.
  • Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309
  • Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18(1):47–66. doi:10.1016/j.beem.2003.08.002
  • Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. medRxiv. 2020. doi:10.1101/2020.03.16.20037143
  • Benjamin Birnbaum NN, Seidl-Rathkopf K, Agrawal M, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research; 2020. Available from: https://arxiv.org/abs/2001.09765. Accessed January 5, 2021.
  • Tunes-da-Silva G, Klein JP. Cutpoint selection for discretizing a continuous covariate for generalized estimating equations. Comput Stat Data Anal. 2011;55(1):226–235. doi:10.1016/j.csda.2010.02.016
  • Luo C, Zhong X, Fan Y, Wu Y, Zheng H, Luo T. Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer. Breast. 2022;63:24–28. doi:10.1016/j.breast.2022.03.002
  • Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat. 2021;188(1):225–235. doi:10.1007/s10549-021-06148-0
  • Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.4147
  • Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv. 2021;15(1):29–39. doi:10.1007/s11764-020-00908-5
  • Yi M, Huo L, Koenig KB, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25(5):1004–1011. doi:10.1093/annonc/mdu053

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.